CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗 B 细胞急性淋巴细胞白血病
英文原题：CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
查看英文原题
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
B细胞急性淋巴细胞白血病（B-ALL）是儿童人群中最常见的急性白血病亚型。过去十年，随着强化且长期的联合化疗方案得到应用，B-ALL的预后和治疗已有显著改善。blinatumomab和inotuzumab等新型免疫药物改变了B-ALL治疗格局。然而患者仍会复发，因此亟需新疗法。嵌合抗原受体（CAR）T细胞已成为B-ALL治疗中的里程碑式进展。美国食品药品监督管理局和欧洲药品管理局已批准两种靶向CD19的CAR-T 细胞产品，用于治疗复发和/或难治性B-ALL。本综述回顾靶向CD19 CAR-T 细胞的现有数据及其安全性特征，并讨论这些疗法的耐药机制和克服耐药的方法。
展开英文摘要原文
B-cell acute lymphoblastic leukemia (B-ALL) is the most common subtype of acute leukemia in the pediatric population. The prognosis and treatment of B-ALL have dramatically improved over the past decade with the adoption of intensive and prolonged combination chemotherapy regimens. The advent of novel immunologic agents such as blinatumomab and inotuzumab has changed the treatment landscape of B-ALL.
However, patients have continued to relapse, raising the need for novel therapies. Chimeric antigen receptor (CAR) T-cells have achieved a milestone in the treatment of B-ALL. Two CD19-targeting CAR T-cells were approved by the Food and Drug Administration and the European Medicines Agency for the treatment of relapsed and/or refractory B-ALL. In this review, we review the available data regarding CD19-targeting CAR T-cells with their safety profile as well as the mechanism of resistance to these agents and the way to overcome this resistance.
论文信息
- 作者
- Saleh K、Pasquier F、Bigenwald C、De Botton S、Ribrag V、Castilla-Llorente C
- 第一作者单位
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.France
- 通讯作者单位
- Department of Hematology, Gustave Roussy Cancer Campus, 94800 Villejuif, France.France
- 文献类型
- 综述
- 期刊
- Journal of clinical medicine2023 Oct 31
- 原文标识
- PubMed 37959347 · DOI 10.3390/jcm12216883
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →